Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Johnson & Johnson (JNJ) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 131,900 employees
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Total Value
-$13,020,167.72
Total Shares
113,566
Average Trade Value
-$140,001.80
Most Active Insider
Duato Joaquin
Total Activity: $30,198,152
Largest Single Transaction
$15,410,456
by Duato Joaquin on Feb 7, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
VP Corporate Controller
Officer
|
Feb 25, 2025 | 6,999 | $712,988 | 28,000 (+25.0%) | Exercise/Conversion | |
VP Corporate Controller
Officer
|
Feb 25, 2025 | 6,999 | $1,160,994 | 21,001 (-33.3%) | Sale | |
Evp, Chief to and Risk Officer
Officer
|
Feb 18, 2025 | 200 | $31,230 | 90,836 (-0.2%) | Payment of Exercise Price | |
Executive Vp, General Counsel
Officer
|
Feb 18, 2025 | 307 | $47,938 | 10,014 (-3.1%) | Payment of Exercise Price | |
VP Corporate Controller
Officer
|
Feb 18, 2025 | 94 | $14,678 | 20,022 (-0.5%) | Payment of Exercise Price | |
CEO and Chairman of the Board
Director, Officer
|
Feb 18, 2025 | 1,602 | $250,152 | 395,923 (-0.4%) | Payment of Exercise Price | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 18, 2025 | 651 | $101,654 | 170,459 (-0.4%) | Payment of Exercise Price | |
Evp, Chief Hr Officer
Officer
|
Feb 18, 2025 | 120 | $18,738 | 12,975 (-0.9%) | Payment of Exercise Price | |
Exec Vp, CFO
Officer
|
Feb 18, 2025 | 768 | $119,923 | 5,345 (-14.4%) | Payment of Exercise Price | |
Evp, Ww Chair, Medtech
Officer
|
Feb 18, 2025 | 403 | $62,928 | 15,098 (-2.7%) | Sale | |
Evp, Innovative Medicine, Rd
Officer
|
Feb 18, 2025 | 385 | $60,118 | 15,542 (-2.5%) | Payment of Exercise Price | |
Evp, Cio
Officer
|
Feb 18, 2025 | 141 | $22,017 | 16,620 (-0.8%) | Payment of Exercise Price | |
Evp, Global Corp Affairs
Officer
|
Feb 18, 2025 | 158 | $24,672 | 21,681 (-0.7%) | Payment of Exercise Price | |
Evp, Cio
Officer
|
Feb 15, 2025 | 492 | $0 | 16,761 (+2.9%) | Exercise/Conversion | |
Exec Vp, CFO
Officer
|
Feb 15, 2025 | 1,971 | $0 | 6,113 (+32.2%) | Exercise/Conversion | |
Evp, Innovative Medicine, Rd
Officer
|
Feb 15, 2025 | 1,350 | $10,000 | 15,927 (+8.5%) | Exercise/Conversion | |
CEO and Chairman of the Board
Director, Officer
|
Feb 15, 2025 | 3,682 | $0 | 397,525 (+0.9%) | Exercise/Conversion | |
Evp, Chief to and Risk Officer
Officer
|
Feb 15, 2025 | 607 | $0 | 91,036 (+0.7%) | Exercise/Conversion | |
Executive Vp, General Counsel
Officer
|
Feb 15, 2025 | 961 | $0 | 10,321 (+9.3%) | Exercise/Conversion | |
Evp, Global Corp Affairs
Officer
|
Feb 15, 2025 | 492 | $0 | 21,839 (+2.3%) | Exercise/Conversion | |
Evp, Ww Chair, Medtech
Officer
|
Feb 15, 2025 | 1,029 | $0 | 15,501 (+6.6%) | Exercise/Conversion | |
VP Corporate Controller
Officer
|
Feb 15, 2025 | 339 | $0 | 20,116 (+1.7%) | Exercise/Conversion | |
Evp, Chief Hr Officer
Officer
|
Feb 15, 2025 | 419 | $0 | 13,095 (+3.2%) | Exercise/Conversion | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 15, 2025 | 1,594 | $0 | 171,110 (+0.9%) | Exercise/Conversion | |
Evp, Cio
Officer
|
Feb 14, 2025 | 152 | $23,600 | 14,866 (-1.0%) | Payment of Exercise Price | |
Evp, Cio
Officer
|
Feb 14, 2025 | 3,118 | $0 | 19,738 (+15.8%) | Exercise/Conversion | |
Evp, Cio
Officer
|
Feb 14, 2025 | 1,961 | $0 | 16,827 (+11.7%) | Exercise/Conversion | |
Evp, Cio
Officer
|
Feb 14, 2025 | 558 | $87,444 | 16,269 (-3.4%) | Payment of Exercise Price | |
Evp, Cio
Officer
|
Feb 14, 2025 | 889 | $139,315 | 18,849 (-4.7%) | Payment of Exercise Price | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 14, 2025 | 1,348 | $211,245 | 169,516 (-0.8%) | Payment of Exercise Price | |
Evp, Chief Hr Officer
Officer
|
Feb 14, 2025 | 1,601 | $10,000 | 14,576 (+11.0%) | Exercise/Conversion | |
Executive Vp, General Counsel
Officer
|
Feb 14, 2025 | 851 | $0 | 9,627 (+8.8%) | Exercise/Conversion | |
Evp, Global Corp Affairs
Officer
|
Feb 14, 2025 | 151 | $23,444 | 20,091 (-0.8%) | Payment of Exercise Price | |
Executive Vp, General Counsel
Officer
|
Feb 14, 2025 | 215 | $33,381 | 8,776 (-2.4%) | Payment of Exercise Price | |
Executive Vp, General Counsel
Officer
|
Feb 14, 2025 | 267 | $41,842 | 9,360 (-2.9%) | Payment of Exercise Price | |
Evp, Global Corp Affairs
Officer
|
Feb 14, 2025 | 2,910 | $0 | 24,591 (+11.8%) | Exercise/Conversion | |
Executive Vp, General Counsel
Officer
|
Feb 14, 2025 | 464 | $72,713 | 10,902 (-4.3%) | Payment of Exercise Price | |
Evp, Ww Chair, Medtech
Officer
|
Feb 14, 2025 | 2,806 | $10,000 | 17,904 (+15.7%) | Exercise/Conversion | |
CEO and Chairman of the Board
Director, Officer
|
Feb 14, 2025 | 2,198 | $344,449 | 393,843 (-0.6%) | Payment of Exercise Price | |
CEO and Chairman of the Board
Director, Officer
|
Feb 14, 2025 | 1,510 | $234,443 | 390,988 (-0.4%) | Payment of Exercise Price | |
CEO and Chairman of the Board
Director, Officer
|
Feb 14, 2025 | 8,386 | $1,314,170 | 406,819 (-2.1%) | Payment of Exercise Price | |
CEO and Chairman of the Board
Director, Officer
|
Feb 14, 2025 | 5,053 | $0 | 396,041 (+1.3%) | Exercise/Conversion | |
Evp, Chief Hr Officer
Officer
|
Feb 14, 2025 | 141 | $21,892 | 11,959 (-1.2%) | Payment of Exercise Price | |
Evp, Chief Hr Officer
Officer
|
Feb 14, 2025 | 1,007 | $0 | 12,966 (+7.8%) | Exercise/Conversion | |
VP Corporate Controller
Officer
|
Feb 14, 2025 | 254 | $39,804 | 19,777 (-1.3%) | Payment of Exercise Price | |
VP Corporate Controller
Officer
|
Feb 14, 2025 | 104 | $16,147 | 19,181 (-0.5%) | Payment of Exercise Price | |
VP Corporate Controller
Officer
|
Feb 14, 2025 | 850 | $0 | 20,031 (+4.2%) | Exercise/Conversion | |
VP Corporate Controller
Officer
|
Feb 14, 2025 | 1,351 | $0 | 21,373 (+6.3%) | Exercise/Conversion | |
VP Corporate Controller
Officer
|
Feb 14, 2025 | 372 | $58,296 | 21,001 (-1.8%) | Payment of Exercise Price | |
Evp, Chief to and Risk Officer
Officer
|
Feb 14, 2025 | 223 | $34,623 | 89,379 (-0.2%) | Payment of Exercise Price | |
Evp, Chief to and Risk Officer
Officer
|
Feb 14, 2025 | 1,530 | $0 | 90,909 (+1.7%) | Exercise/Conversion | |
Evp, Chief to and Risk Officer
Officer
|
Feb 14, 2025 | 2,393 | $375,007 | 94,280 (-2.5%) | Payment of Exercise Price | |
Evp, Chief to and Risk Officer
Officer
|
Feb 14, 2025 | 5,837 | $0 | 96,673 (+6.0%) | Exercise/Conversion | |
Evp, Ww Chair, Medtech
Officer
|
Feb 14, 2025 | 1,765 | $0 | 15,111 (+11.7%) | Exercise/Conversion | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 14, 2025 | 410 | $63,657 | 166,811 (-0.2%) | Payment of Exercise Price | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 14, 2025 | 4,053 | $0 | 170,864 (+2.4%) | Exercise/Conversion | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 14, 2025 | 15,465 | $0 | 185,924 (+8.3%) | Exercise/Conversion | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 14, 2025 | 7,911 | $1,239,733 | 178,013 (-4.4%) | Payment of Exercise Price | |
Exec Vp, CFO
Officer
|
Feb 14, 2025 | 1,144 | $179,276 | 4,142 (-27.6%) | Payment of Exercise Price | |
Exec Vp, CFO
Officer
|
Feb 14, 2025 | 4,014 | $0 | 5,286 (+75.9%) | Exercise/Conversion | |
Exec Vp, CFO
Officer
|
Feb 14, 2025 | 6,661 | $1,043,845 | 14,000 (-47.6%) | Payment of Exercise Price | |
Exec Vp, CFO
Officer
|
Feb 14, 2025 | 15,316 | $0 | 20,661 (+74.1%) | Exercise/Conversion | |
Exec Vp, CFO
Officer
|
Feb 14, 2025 | 507 | $78,717 | 1,272 (-39.9%) | Payment of Exercise Price | |
Evp, Global Corp Affairs
Officer
|
Feb 14, 2025 | 1,830 | $0 | 21,921 (+8.3%) | Exercise/Conversion | |
Evp, Global Corp Affairs
Officer
|
Feb 14, 2025 | 574 | $89,952 | 21,347 (-2.7%) | Payment of Exercise Price | |
Executive Vp, General Counsel
Officer
|
Feb 14, 2025 | 1,352 | $0 | 11,366 (+11.9%) | Exercise/Conversion | |
Evp, Global Corp Affairs
Officer
|
Feb 14, 2025 | 997 | $156,240 | 23,594 (-4.2%) | Payment of Exercise Price | |
Evp, Ww Chair, Medtech
Officer
|
Feb 14, 2025 | 1,015 | $159,061 | 16,889 (-6.0%) | Payment of Exercise Price | |
CEO and Chairman of the Board
Director, Officer
|
Feb 14, 2025 | 19,282 | $0 | 415,205 (+4.6%) | Exercise/Conversion | |
Evp, Chief Hr Officer
Officer
|
Feb 14, 2025 | 290 | $45,446 | 12,676 (-2.3%) | Payment of Exercise Price | |
Evp, Chief Hr Officer
Officer
|
Feb 14, 2025 | 457 | $71,616 | 14,119 (-3.2%) | Payment of Exercise Price | |
Evp, Chief to and Risk Officer
Officer
|
Feb 14, 2025 | 480 | $75,221 | 90,429 (-0.5%) | Payment of Exercise Price | |
Evp, Ww Chair, Medtech
Officer
|
Feb 14, 2025 | 193 | $29,965 | 13,346 (-1.4%) | Payment of Exercise Price | |
Evp, Ww Chair, Medtech
Officer
|
Feb 14, 2025 | 639 | $100,138 | 14,472 (-4.4%) | Payment of Exercise Price | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 13, 2025 | 1,302 | $0 | 167,221 (+0.8%) | Exercise/Conversion | |
Evp, Chief to and Risk Officer
Officer
|
Feb 13, 2025 | 651 | $0 | 89,602 (+0.7%) | Exercise/Conversion | |
CEO and Chairman of the Board
Director, Officer
|
Feb 13, 2025 | 3,470 | $0 | 392,498 (+0.9%) | Exercise/Conversion | |
Evp, Ww Chair, Medtech
Officer
|
Feb 13, 2025 | 499 | $0 | 13,539 (+3.7%) | Exercise/Conversion | |
Evp, Global Corp Affairs
Officer
|
Feb 13, 2025 | 408 | $0 | 20,242 (+2.0%) | Exercise/Conversion | |
Exec Vp, CFO
Officer
|
Feb 13, 2025 | 1,779 | $0 | 1,779 (+100.0%) | Exercise/Conversion | |
Executive Vp, General Counsel
Officer
|
Feb 13, 2025 | 651 | $0 | 8,991 (+7.2%) | Exercise/Conversion | |
VP Corporate Controller
Officer
|
Feb 13, 2025 | 312 | $0 | 19,285 (+1.6%) | Exercise/Conversion | |
Evp, Chief Hr Officer
Officer
|
Feb 13, 2025 | 411 | $0 | 12,100 (+3.4%) | Exercise/Conversion | |
Evp, Cio
Officer
|
Feb 13, 2025 | 447 | $0 | 15,018 (+3.0%) | Exercise/Conversion | |
Evp, Chief to and Risk Officer
Officer
|
Feb 7, 2025 | 32,762 | $3,278,166 | 115,027 (+28.5%) | Exercise/Conversion | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 7, 2025 | 58,504 | $5,853,910 | 213,355 (+27.4%) | Exercise/Conversion | |
Evp, Wwc. Innovative Medicine
Officer
|
Feb 7, 2025 | 47,436 | $7,263,400 | 165,919 (-28.6%) | Payment of Exercise Price | |
Evp, Chief to and Risk Officer
Officer
|
Feb 7, 2025 | 26,076 | $3,992,757 | 88,951 (-29.3%) | Payment of Exercise Price | |
Exec Vp, CFO
Officer
|
Feb 7, 2025 | 13,015 | $2,002,878 | 0 | Sale | |
Exec Vp, CFO
Officer
|
Feb 7, 2025 | 13,015 | $1,302,281 | 13,015 (+100.0%) | Exercise/Conversion | |
CEO and Chairman of the Board
Director, Officer
|
Feb 7, 2025 | 126,369 | $12,644,482 | 489,671 (+25.8%) | Exercise/Conversion | |
CEO and Chairman of the Board
Director, Officer
|
Feb 7, 2025 | 100,643 | $15,410,456 | 389,028 (-25.9%) | Payment of Exercise Price | |
Director
|
Dec 12, 2024 | 1,000 | $147,220 | 1,000 (+100.0%) | Purchase |